Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1970 1
1971 5
1972 5
1973 4
1974 4
1975 5
1976 5
1977 6
1978 3
1979 6
1980 6
1981 3
1982 12
1983 16
1984 5
1985 12
1986 8
1987 11
1988 9
1989 16
1990 17
1991 13
1992 19
1993 17
1994 10
1995 22
1996 19
1997 15
1998 14
1999 19
2000 26
2001 20
2002 17
2003 20
2004 22
2005 21
2006 20
2007 14
2008 23
2009 14
2010 10
2011 5
2012 17
2013 13
2014 7
2015 9
2016 8
2017 8
2018 7
2019 7
2020 12
2021 4
2022 17
2023 13
2024 9
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

641 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fischer-Riepe L, Kailayangiri S, Zimmermann K, Pfeifer R, Aigner M, Altvater B, Kretschmann S, Völkl S, Hartley J, Dreger C, Petry K, Bosio A, von Döllen A, Hartmann W, Lode H, Görlich D, Mackensen A, Jungblut M, Schambach A, Abken H, Rossig C. Fischer-Riepe L, et al. Among authors: lode h. Clin Cancer Res. 2024 Aug 15;30(16):3564-3577. doi: 10.1158/1078-0432.CCR-23-3157. Clin Cancer Res. 2024. PMID: 38593230
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma.
Rouaen JRC, Salerno A, Shai-Hee T, Murray JE, Castrogiovanni G, McHenry C, Jue TR, Pham V, Bell JL, Poursani E, Valli E, Cazzoli R, Damstra N, Nelson DJ, Stevens KLP, Chee J, Slapetova I, Kasherman M, Whan R, Lin F, Cochran BJ, Tedla N, Veli FC, Yuksel A, Mayoh C, Saletta F, Mercatelli D, Chtanova T, Kulasinghe A, Catchpoole D, Cirillo G, Biro M, Lode HN, Luciani F, Haber M, Gray JC, Trahair TN, Vittorio O. Rouaen JRC, et al. Among authors: lode hn. Nat Commun. 2024 Dec 12;15(1):10462. doi: 10.1038/s41467-024-54689-x. Nat Commun. 2024. PMID: 39668192 Free PMC article.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: lode hn. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
[Systemic antimycotic treatment].
Höffken G, Lode H. Höffken G, et al. Among authors: lode h. Dtsch Med Wochenschr. 1982 Sep 24;107(38):1446-50. doi: 10.1055/s-2008-1070147. Dtsch Med Wochenschr. 1982. PMID: 6288340 Review. German. No abstract available.
Pharmacodynamics of fluoroquinolones.
Lode H, Borner K, Koeppe P. Lode H, et al. Clin Infect Dis. 1998 Jul;27(1):33-9. doi: 10.1086/514623. Clin Infect Dis. 1998. PMID: 9675446 Review.
Pneumococcal vaccination.
de Roux A, Lode H. de Roux A, et al. Among authors: lode h. Eur Respir J. 2005 Dec;26(6):982-3. doi: 10.1183/09031936.05.00119705. Eur Respir J. 2005. PMID: 16319323 Free article. No abstract available.
Toxicity of quinolones.
Stahlmann R, Lode H. Stahlmann R, et al. Among authors: lode h. Drugs. 1999;58 Suppl 2:37-42. doi: 10.2165/00003495-199958002-00007. Drugs. 1999. PMID: 10553703 Review.
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin KM, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Tröger A, Koller M, Menhart K, Riemenschneider MJ, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdörfer P, Kühnle I, Dilloo D, Schönberger S, Schwabe G, von Luettichau I, Graf N, Schlegel PG, Frühwald M, Jorch N, Paulussen M, Schneider DT, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Fröhlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, Foell J. Corbacioglu S, et al. Among authors: lode h. Lancet Oncol. 2024 Jul;25(7):922-932. doi: 10.1016/S1470-2045(24)00202-X. Lancet Oncol. 2024. PMID: 38936379 Free article. Clinical Trial.
Preface.
Lode H. Lode H. Int J Antimicrob Agents. 1996 Apr;6 Suppl:v-vi. doi: 10.1016/s0924-8579(96)80000-8. Int J Antimicrob Agents. 1996. PMID: 18611727 No abstract available.
641 results